Academic Bibliography

 Search 200 years of publications by Ghent University researchers.
Advanced search
1 file | 260.44 KB
  1. Search results
  2. Seventeen-year antibody persistence i...

Seventeen-year antibody persistence in adults primed with two doses of an inactivated hepatitis A vaccine

Koen Van Herck (UGent) , Priya Diana Crasta, Marc Messier, Karin Hardt and Pierre Van Damme
(2012) HUMAN VACCINES & IMMUNOTHERAPEUTICS. 8(3).
Author
Organization
Abstract
Background and objectives: Antibody persistence and immune memory against hepatitis A (HAV) in adults in a low endemicity country, 15 y after immunisation with two doses of HAV vaccine has been demonstrated. This communication provides additional information on antibody persistence up to Year 17 from two of the longest follow-up studies [NCT00289757/NCT00291876]. Methods: In two double-blind primary studies, healthy adults aged 17-40 y and 21-40 y, respectively received two doses of the HAV vaccine following a 0,6 mo or 0,12 mo schedule. Anti-HAV antibody concentrations were measured using an enzyme-linked immunoassay (cut-off: 15mIU/ml) at Year 16 and Year 17. Subjects who became seronegative (anti-HAV < 15mIU/ml) since previous reporting were offered a challenge dose, with anti-HAV antibody concentration measurements at Day 14 and Day 30 thereafter. Results: At Year 17, 100% and 96.7% of subjects remained seropositive for anti-HAV antibodies following the 0, 6 mo and 0, 12 mo regimens, respectively (GMCs: 278mIU/ml and 369mIU/ml). One subject who became seronegative at Year 16 received a HAV challenge dose within the next 12 mo and mounted an anamnestic response. The challenge dose was well-tolerated. Conclusions: Both HAV immunisation regimens (0,6 mo and 0,12 mo) induced persistence of vaccine-induced antibodies against HAV for at least 17 y after primary vaccination.
Keywords
Hepatitis, HAV, monovalent, persistence, immune memory, vaccine, LONG-TERM PERSISTENCE, IMMUNE MEMORY, FOLLOW-UP

Downloads

  • Download
    (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 260.44 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Van Herck, Koen, Priya Diana Crasta, Marc Messier, Karin Hardt, and Pierre Van Damme. 2012. “Seventeen-year Antibody Persistence in Adults Primed with Two Doses of an Inactivated Hepatitis A Vaccine.” Human Vaccines & Immunotherapeutics 8 (3).
APA
Van Herck, Koen, Crasta, P. D., Messier, M., Hardt, K., & Van Damme, P. (2012). Seventeen-year antibody persistence in adults primed with two doses of an inactivated hepatitis A vaccine. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 8(3).
Vancouver
1.
Van Herck K, Crasta PD, Messier M, Hardt K, Van Damme P. Seventeen-year antibody persistence in adults primed with two doses of an inactivated hepatitis A vaccine. HUMAN VACCINES & IMMUNOTHERAPEUTICS. 2012;8(3).
MLA
Van Herck, Koen, Priya Diana Crasta, Marc Messier, et al. “Seventeen-year Antibody Persistence in Adults Primed with Two Doses of an Inactivated Hepatitis A Vaccine.” HUMAN VACCINES & IMMUNOTHERAPEUTICS 8.3 (2012): n. pag. Print.
@article{2151178,
  abstract     = {Background and objectives: Antibody persistence and immune memory against hepatitis A (HAV) in adults in a low endemicity country, 15 y after immunisation with two doses of HAV vaccine has been demonstrated. This communication provides additional information on antibody persistence up to Year 17 from two of the longest follow-up studies [NCT00289757/NCT00291876]. 
Methods: In two double-blind primary studies, healthy adults aged 17-40 y and 21-40 y, respectively received two doses of the HAV vaccine following a 0,6 mo or 0,12 mo schedule. Anti-HAV antibody concentrations were measured using an enzyme-linked immunoassay (cut-off: 15mIU/ml) at Year 16 and Year 17. Subjects who became seronegative (anti-HAV {\textlangle} 15mIU/ml) since previous reporting were offered a challenge dose, with anti-HAV antibody concentration measurements at Day 14 and Day 30 thereafter. 
Results: At Year 17, 100\% and 96.7\% of subjects remained seropositive for anti-HAV antibodies following the 0, 6 mo and 0, 12 mo regimens, respectively (GMCs: 278mIU/ml and 369mIU/ml). One subject who became seronegative at Year 16 received a HAV challenge dose within the next 12 mo and mounted an anamnestic response. The challenge dose was well-tolerated. 
Conclusions: Both HAV immunisation regimens (0,6 mo and 0,12 mo) induced persistence of vaccine-induced antibodies against HAV for at least 17 y after primary vaccination.},
  author       = {Van Herck, Koen and Crasta, Priya Diana and Messier, Marc and Hardt, Karin and Van Damme, Pierre},
  issn         = {2164-5515},
  journal      = {HUMAN VACCINES \& IMMUNOTHERAPEUTICS},
  keyword      = {Hepatitis,HAV,monovalent,persistence,immune memory,vaccine,LONG-TERM PERSISTENCE,IMMUNE MEMORY,FOLLOW-UP},
  language     = {eng},
  number       = {3},
  pages        = {5},
  title        = {Seventeen-year antibody persistence in adults primed with two doses of an inactivated hepatitis A vaccine},
  url          = {http://dx.doi.org/10.4161/hv.8.3.18617},
  volume       = {8},
  year         = {2012},
}
Altmetric
View in Altmetric
Web of Science
Times cited: